Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
about
Novel therapeutic strategies targeting HIV integraseDevelopment of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutationsHIV-1 Genetic Variability and Clinical ImplicationsA national study of the molecular epidemiology of HIV-1 in Australia 2005-2012Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates.Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.Increasing HIV subtype diversity and its clinical implications in a sentinel North American populationThe Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug ResistanceAre subtype differences important in HIV drug resistance?HIV Drug Resistance and the Advent of Integrase Inhibitors.Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters.Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.Antiviral Activity of Bictegravir and Cabotegravir Against Integrase Inhibitor Resistant SIVmac239 and HIV-1.Serological pattern of Hepatitis B, C, and HIV infections among immigrants in Sicily: epidemiological aspects and implication on public health.Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.A high HIV-1 strain variability in London, UK, revealed by full-genome analysis: Results from the ICONIC project.Genotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in "Real-World" Settings.Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals.Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
P2860
Q27003960-34CD8D6D-8592-406A-AC05-5A07B9888C67Q28481393-3324B057-3D15-42FE-88B8-620DC1B9504CQ30352010-DAF28961-96DC-4BCB-B782-E4DCEDCD9F8DQ33657146-97FD3AEB-FED9-4466-8A06-45274281729CQ35607740-1390A700-7CAF-408F-BE3D-89AB6E33E4CCQ36077418-19A528A5-CF96-4C98-8189-23F650F9140AQ36185311-532923F4-23A2-4BE2-83F8-AB9980540990Q36284159-E1693282-E141-4A7D-BD1F-029FE8049DC2Q36336395-706268A6-DB7E-4F63-AB4C-8ED26228FCBAQ36458517-408F16C2-703C-411D-880C-00C573ABE269Q36977388-72D5F458-3299-4198-B967-88A592121138Q37037315-15F4A4EF-BB64-4A25-A352-DDF253F91E4BQ37288671-7468B375-116D-403A-8137-7E8C3D74026FQ37633109-6115E45C-435A-4A65-8416-EA9C0A26959BQ38062462-49E6CAA1-02B5-4577-9043-9D5093444E6DQ39421000-0D4F066B-E778-4338-BAEF-D0F097A8DF73Q40215127-034CAF96-BEA3-412F-A40E-926F1515FBA8Q41716674-29B69A56-ADA3-4F24-B68C-EE62BC162C68Q41935102-B24F4DC0-934A-4B93-828F-368205C4D5EAQ45769211-561A0E26-07AB-404A-AF2C-7187458B97EEQ47130258-8D01C280-CBD5-45D0-AE4C-DB55F015718FQ47547162-50519C10-5ABB-447A-A7E7-E906A6CE9167Q47560008-CC4DB993-5EB7-4398-8414-BFB9902AC20AQ51039642-80067412-D2B3-4CE6-84A0-4CAEEC656023Q54520623-37664EE7-88CA-4836-A77E-20B0D51C2E83Q58770498-38E26754-5AB1-4833-BADD-E9A4665A40AC
P2860
Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Subtype diversity associated w ...... tance to integrase inhibitors.
@en
Subtype diversity associated w ...... tance to integrase inhibitors.
@nl
type
label
Subtype diversity associated w ...... tance to integrase inhibitors.
@en
Subtype diversity associated w ...... tance to integrase inhibitors.
@nl
prefLabel
Subtype diversity associated w ...... tance to integrase inhibitors.
@en
Subtype diversity associated w ...... tance to integrase inhibitors.
@nl
P2093
P2860
P356
P1476
Subtype diversity associated w ...... tance to integrase inhibitors.
@en
P2093
Bluma G Brenner
Daniela Moisi
Isabelle Hardy
Jean Guy Baril
Mark A Wainberg
Matthew Lowe
Michel Roger
Simon Gagnon
P2860
P304
P356
10.1002/JMV.22047
P577
2011-02-25T00:00:00Z